Table 1.
Comparison of the SERC trial and the French cohort (G3S) populations.
| Sentinel Node Micro-Metastases | Characteristics | SERC | G3S | Chi 2 | ||
|---|---|---|---|---|---|---|
| n | % | n | % | p-value | ||
| All patients | 471 | 1863 | ||||
| Age | ≥40 | 24 | 5.10 | 135 | 7.30 | <0.05 |
| 41–75 | 432 | 91.72 | 1632 | 87.60 | ||
| >75 | 15 | 3.18 | 95 | 5.10 | ||
| Missing data | 0 | 1 | ||||
| Median (range) | 58 (26–83) | 56 (25–94) | ||||
| pT stage | pT1 | 297 | 63.46 | 1266 | 67.90 | 0.001 |
| pT2 | 155 | 33.12 | 522 | 28.00 | ||
| pT3 | 6 | 1.28 | 55 | 3.00 | ||
| pT4 | 2 | 0.43 | ||||
| Missing data | 11 | 20 | 1.10 | |||
| pT size | ≤10 | 87 | 18.59 | 453 | 24.60 | <0.01 |
| 10 to 30 | 334 | 71.37 | 1256 | 68.30 | ||
| >30 | 47 | 10.04 | 130 | 7.10 | ||
| Missing data | 3 | 24 | ||||
| Tumor size | Mean | 18.73 | 18.1 | |||
| T histology | Ductal | 373 | 79.36 | 1515 | 81.30 | 0.40 |
| Lobular | 47 | 10.00 | 173 | 9.30 | ||
| Mixed | 15 | 3.19 | 39 | 2.10 | ||
| Others | 35 | 7.45 | 119 | 6.40 | ||
| Missing data | 1 | 17 | 0.90 | |||
| Grade | 1 | 125 | 27.29 | 641 | 34.40 | <0.01 |
| 2 | 234 | 51.09 | 872 | 46.80 | ||
| 3 | 99 | 21.62 | 308 | 16.50 | ||
| Missing data | 13 | 42 | 2.30 | |||
| LVI | No | 334 | 74.22 | 1192 | 64.00 | >0.05 |
| Yes | 116 | 25.78 | 516 | 27.70 | ||
| Missing data | 21 | 155 | 8.30 | |||
| ER | Negative | 44 | 9.50 | 148 | 8.20 | 0.40 |
| Positive | 419 | 90.50 | 1661 | 91.80 | ||
| Missing data | 8 | 54 | ||||
| PR | Negative | 89 | 19.18 | 388 | 22.70 | 0.15 |
| Positive | 375 | 80.82 | 1321 | 77.30 | ||
| Missing data | 7 | 154 | ||||
| Endocrine Receptors | Negative | 44 | 9.48 | 129 | 6.90 | >0.05 |
| Positive | 420 | 90.52 | 1707 | 91.60 | ||
| Missing data | 7 | 27 | 1.40 | |||
| Her2 | Negative | 403 | 89.56 | 1100 | 95.60 | 0.15 |
| Positive | 47 | 10.44 | 95 | 4.40 | ||
| Missing data | 21 | 668 | ||||
| T phenotype | ER+ Her2+ | 37 | 8.24 | 67 | 5.60 | 0.20 |
| ER+ Her2- | 373 | 83.07 | 1034 | 86.70 | ||
| ER- Her2+ | 10 | 2.23 | 28 | 2.30 | ||
| ER- Her2- | 29 | 6.46 | 64 | 5.40 | ||
| Missing data | 22 | 670 | ||||
| SN number | ≤2 | 344 | 73.04 | 940 | 63.00 | <0.001 |
| >2 | 127 | 26.96 | 551 | 37.00 | ||
| Missing data | 0 | 372 | ||||
| Positive SN number | ≤2 | 465 | 99.15 | 1481 | 99.30 | 0.60 |
| >2 | 4 | 0.85 | 10 | 0.70 | ||
| Missing data | 2 | 372 | ||||
| pN status final | pN1mi | 198 | 95.19 | 1710 | 91.80 | 0.09 |
| pN1macro | 10 | 4.81 | 153 | 8.20 | ||
| Missing data | ||||||
| Chemotherapy | No | 202 | 43.53 | 761 | 40.80 | 0.80 |
| NAC (Neoadjuvant chemotherapy) | 11 | 2.37 | 37 | 2.00 | ||
| AC (Adjuvant chemotherapy) | 251 | 54.09 | 992 | 53.20 | ||
| Missing data | 7 | 73 | 3.90 | |||
| Surgery | Conservative | 388 | 82.55 | 1554 | 83.40 | 0.18 |
| Mastectomy | 82 | 17.45 | 274 | 14.70 | ||
| Missing data | 1 | 35 | 1.90 | |||
| Endocrine therapy | No | 40 | 10.13 | 199 | 11.10 | 0.50 |
| Yes | 355 | 89.87 | 1594 | 88.90 | ||
| Missing data | 76 | 70 | ||||
| Trastuzumab | No | 291 | 88.45 | 1118 | 93.50 | <0.01 |
| Yes | 38 | 11.55 | 77 | 6.05 | ||
| Missing data | 142 | 668 | ||||
| Radiotherapy | No | 27 | 5.87 | 113 | 6.50 | 0.50 |
| Yes | 433 | 94.13 | 1636 | 93.50 | ||
| Missing data | 11 | 114 | ||||
| Internal Mammary Chain radiotherapy | No | 269 | 64.35 | 805 | 51.40 | <0.001 |
| Yes | 149 | 35.65 | 761 | 48.60 | ||
| Missing data | 53 | 297 | ||||
| Clavicular radiotherapy | No | 183 | 43.57 | 751 | 48.00 | 0.10 |
| Yes | 237 | 56.43 | 814 | 52.00 | ||
| Missing data | 51 | 298 | ||||
| Treatment realized | ALND | 216 | 45.96 | 1588 | 85.20 | <0.0001 |
| SLNB | 254 | 54.04 | 275 | 14.80 | ||
| Eligibility Z0011 | No | 119 | 27.67 | 126 | 9.30 | <0.0001 |
| Yes | 311 | 72.33 | 1226 | 90.70 | ||
| Missing data | 41 | |||||
| NSN status at cALND | pN0 | 192 | 89.72 | 1188 | 88.70 | 0.50 |
| pN1macro | 22 | 10.28 | 152 | 11.30 | ||